Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded
to previous treatment. Imatinib mesylate may stop the growth of tumor cells by blocking the
enzymes necessary for cancer cell growth